General Information of the Protein
Protein ID
PT02021
Protein Name
Transitional endoplasmic reticulum ATPase
Secondarily
Protein Name
15S Mg(2+)-ATPase p97 subunit
Valosin-containing protein
Gene Name
VCP
Secondarily
Gene Name
HEL-220
HEL-S-70
Sequence
MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Transporter
>
Primary active transporter
>
Endoplasmic reticular retrotranslocon family
Function
Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. Regulates E3 ubiquitin-protein ligase activity of RNF19A. Component of the VCP/p97-AMFR/gp78 complex that participates in the final step of the sterol-mediated ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Mediates the endoplasmic reticulum-associated degradation of CHRNA3 in cortical neurons as part of the STUB1-VCP-UBXN2A complex (PubMed:26265139). Involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation (PubMed:26565908). Involved in clearance process by mediating G3BP1 extraction from stress granules (PubMed:29804830, PubMed:34739333). Also involved in DNA damage response: recruited to double-strand breaks (DSBs) sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites (PubMed:22020440, PubMed:22120668). Recruited to stalled replication forks by SPRTN: may act by mediating extraction of DNA polymerase eta (POLH) to prevent excessive translesion DNA synthesis and limit the incidence of mutations induced by DNA damage (PubMed:23042607, PubMed:23042605). Together with SPRTN metalloprotease, involved in the repair of covalent DNA-protein cross-links (DPCs) during DNA synthesis (PubMed:32152270). Involved in interstrand cross-link repair in response to replication stress by mediating unloading of the ubiquitinated CMG helicase complex (By similarity). Mediates extraction of PARP1 trapped to chromatin: recognizes and binds ubiquitinated PARP1 and promotes its removal (PubMed:35013556). Required for cytoplasmic retrotranslocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation (PubMed:16186510, PubMed:21118995). Essential for the maturation of ubiquitin-containing autophagosomes and the clearance of ubiquitinated protein by autophagy (PubMed:20104022, PubMed:27753622). Acts as a negative regulator of type I interferon production by interacting with RIGI: interaction takes place when RIGI is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of RIGI (PubMed:26471729). May play a role in the ubiquitin-dependent sorting of membrane proteins to lysosomes where they undergo degradation (PubMed:21822278). May more particularly play a role in caveolins sorting in cells (PubMed:21822278, PubMed:23335559). By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway (PubMed:26692333).
    Show/Hide
Uniprot ID
Primary ID:
P55072

Secondarily ID:
B2R5T8
Q0V924
Q2TAI5
Q969G7
Q9UCD5
V9HW80
    Show/Hide
Ensembl ID
ENSG00000165280
HGNC ID
HGNC:12666
Subcellular Location
Cytoplasm
Cytosol
Endoplasmic reticulum
Nucleus
Cytoplasm
Stress granule
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000068 , A-549
Compound ID Compound Name Compound Formula
CP0234347
1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methylindole-4-carboxamide
   Show/Hide
C25H25N5O
 3
1
IC50 = 250 nM
   TI
   LI
   LO
   TS
2
IC50 = 500 nM
   TI
   LI
   LO
   TS
3
IC50 = 580 nM
   TI
   LI
   LO
   TS
CP0064199
Cb 5083
   Show/Hide
C24H23N5O2
 3
1
IC50 = 490 nM
   TI
   LI
   LO
   TS
2
IC50 = 680 nM
   TI
   LI
   LO
   TS
3
IC50 = 1030 nM
   TI
   LI
   LO
   TS
CP0420601
1-[4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide
   Show/Hide
C24H24N6O
 3
1
IC50 = 1790 nM
   TI
   LI
   LO
   TS
2
IC50 = 2000 nM
   TI
   LI
   LO
   TS
3
IC50 = 2860 nM
   TI
   LI
   LO
   TS
CP0149103
N-benzyl-2-(2-methoxybenzimidazol-1-yl)-5,6,7,8-tetrahydroquinazolin-4-amine
   Show/Hide
C23H23N5O
 3
1
IC50 = 4240 nM
   TI
   LI
   LO
   TS
2
IC50 = 4840 nM
   TI
   LI
   LO
   TS
3
IC50 = 9340 nM
   TI
   LI
   LO
   TS
CP0321487
2-(2-aminobenzimidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine
   Show/Hide
C23H20N6O
 2
1
IC50 = 6140 nM
   TI
   LI
   LO
   TS
2
IC50 = 6610 nM
   TI
   LI
   LO
   TS
CP0099592
US9062026, Table III, Compound 43
   Show/Hide
C23H23N5
 2
1
IC50 = 9150 nM
   TI
   LI
   LO
   TS
2
IC50 = 15320 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0234347
1-[4-(benzylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-2-methylindole-4-carboxamide
   Show/Hide
C25H25N5O
 2
1 IC50 = 6 nM
2 Ki = 28.6 nM
CP0064199
Cb 5083
   Show/Hide
C24H23N5O2
 4
1 IC50 = 11 nM
2 IC50 = 27 nM
3 IC50 = 44 nM
4 Ki = 26.1 nM
CP0420601
1-[4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide
   Show/Hide
C24H24N6O
 1
1 IC50 = 40 nM
CP0015606
4-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol
   Show/Hide
C15H11ClN2OS
 1
1 IC50 = 70 nM
CP0149103
N-benzyl-2-(2-methoxybenzimidazol-1-yl)-5,6,7,8-tetrahydroquinazolin-4-amine
   Show/Hide
C23H23N5O
 1
1 IC50 = 76 nM
CP0069517
4-(4-(thiophen-2-yl)thiazol-2-ylamino)phenol
   Show/Hide
C13H10N2OS2
 1
1 IC50 = 110 nM
CP0321487
2-(2-aminobenzimidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine
   Show/Hide
C23H20N6O
 2
1 IC50 = 110 nM
2 IC50 = 815 nM
CP0063962
3-(2-(4-hydroxyphenylamino)thiazol-4-yl)phenol
   Show/Hide
C15H12N2O2S
 1
1 IC50 = 120 nM
CP0068544
4-(4-phenylthiazol-2-ylamino)phenol
   Show/Hide
C15H12N2OS
 1
1 IC50 = 190 nM
CP0099592
US9062026, Table III, Compound 43
   Show/Hide
C23H23N5
 2
1 IC50 = 192 nM
2 IC50 < 2000 nM
CP0226455
4-(4-(pyridin-2-yl)thiazol-2-ylamino)phenol
   Show/Hide
C14H11N3OS
 1
1 IC50 = 230 nM
CP0030899
1-[(2-chlorophenyl)-diphenylmethyl]imidazole
   Show/Hide
C22H17ClN2
 1
1 IC50 = 12000 nM
CP0177351
2-[3-(4-chlorophenyl)-4-[(4-chlorophenyl)carbamoyl-hydroxyamino]-5,5-dimethyl-2-oxoimidazolidin-1-yl]-N-[(E)-[(E)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]acetamide
   Show/Hide
C27H25Cl2N7O7
 1
1 Kd = 5000 nM
Clinical Information about the Protein
Target 1 ( Valosin-containing protein p97 (VCP) )
Target Type Clinical trial Target
Disease 1 Target-related Disease  1
1 Multiple myeloma [ICD-11: 2A83]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 CB-5083 Phase 1
Multiple myeloma
Target 2 ( HUMAN valosin-containing protein p97 (VCP) )
Target Type Unknown Type Target
Disease 1 Target-related Disease  1
1 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y]
Investigative Drug(s) 1 Investigative Drug  1
1 NMS-873 Investigative
Coronavirus Disease 2019 (COVID-19)